Slow Vaccine Delivery May Maximize Immune Response

A vaccine strategy involving formulation changes, an initial escalating dose, and a longer wait for booster immunization results in more-effective antibody production against HIV in rhesus monkeys, a study finds.

Written byAlejandra Manjarrez, PhD
| 5 min read
A germinal center inside a lymph node
Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

Scientists have spent decades attempting to develop a vaccine for HIV, with limited success. Now, research published in Nature this week (September 21) suggests that the solution to achieving effective protection may partially lie in how the vaccine is delivered. By breaking the initial dose of a vaccine into multiple, escalating doses over the course of nearly two weeks, a team of researchers from the La Jolla Institute for Immunology was able to generate a longer-lasting immune response in rhesus macaques (Macaca mulatta) and higher levels of neutralizing antibodies following a booster dose when compared with a traditional, one-shot approach.

There are still many steps to be taken before this can be translated into HIV treatment for humans, says Elizabeth Connick, who studies HIV pathogenesis and cure strategies at the University of Arizona College of Medicine and was not involved in this study. For example, she says it’s crucial to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • alejandra manjarrez

    Alejandra Manjarrez is a freelance science journalist who contributes to The Scientist. She has a PhD in systems biology from ETH Zurich and a master’s in molecular biology from Utrecht University. After years studying bacteria in a lab, she now spends most of her days reading, writing, and hunting science stories, either while traveling or visiting random libraries around the world. Her work has also appeared in Hakai, The Atlantic, and Lab Times.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies